Karen M. Anderson Sells 5,876 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 5,876 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $17.01, for a total value of $99,950.76. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at $1,216,640.25. The trade was a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Centessa Pharmaceuticals Stock Up 5.1 %

Shares of CNTA traded up $0.85 on Tuesday, reaching $17.60. The company’s stock had a trading volume of 816,790 shares, compared to its average volume of 431,601. The stock has a market capitalization of $2.32 billion, a PE ratio of -11.50 and a beta of 1.52. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The firm has a fifty day moving average of $16.53 and a 200-day moving average of $13.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $4,305,000. Franklin Resources Inc. increased its stake in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares during the period. Geode Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 68.7% during the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock valued at $905,000 after purchasing an additional 23,058 shares in the last quarter. Jane Street Group LLC purchased a new stake in Centessa Pharmaceuticals in the third quarter worth $2,834,000. Finally, Wellington Management Group LLP bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $1,609,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CNTA. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target on the stock. Jefferies Financial Group lifted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Guggenheim lifted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, BMO Capital Markets upped their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.